SALIX PHARMACEUTICALS LTD Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q3 FY2013 As of Sep 30, 2013	Q2 FY2013 As of Jun 30, 2013	Q1 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Dec 31, 2012	Q3 FY2012 As of Sep 30, 2012	Q2 FY2012 As of Jun 30, 2012	Q1 FY2012 As of Mar 31, 2012	Q4 FY2011 As of Dec 31, 2011	Q3 FY2011 As of Sep 30, 2011	Q2 FY2011 As of Jun 30, 2011	Q1 FY2011 As of Mar 31, 2011
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Inventory
Prepaid and other current assets
Deferred tax assets
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Goodwill
Product rights and intangibles, net
Deferred tax assets
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued liabilities
Reserve for product returns, rebates and chargebacks
Income taxes payable
Reserve for product returns, rebates, chargebacks, and patient-focused promotional programs
Current portion of convertible senior notes
Current portion of Term Loan B credit facility
Current portion of acquisition-related contingent consideration
Current portion of capital lease obligations
Total current liabilities

Long-term liabilities:
Convertible senior notes
Convertible Senior Notes
Total convertible senior notes
Lease incentive obligation
Term Loan B credit facility
2021 senior notes
6.60% Senior Notes Due 2021
2021 Notes
Total 2021 senior notes
Acquisition-related contingent consideration
Deferred tax liabilities
Long term portion of capital lease obligations
Other long-term liabilities
Total long-term liabilities

Unamortized debt discount due on conversion of senior notes
Convertible Senior Notes
Total unamortized debt discount due on conversion of senior notes

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized, 63,826,685 and 62,937,966 shares issued and outstanding at December 31, 2014 and 2013, respectively
Additional paid-in-capital
Accumulated other comprehensive income (loss)
Retained earnings (deficit)
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments